Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 827 publications

French recommendations from the AFU Cancer Committee for prostate cancer 2025 Summary of changes.

French recommendations from the AFU Cancer Committee for prostate cancer 2025 Summary of changes.

Journal: The French journal of urology
Published: October 06, 2025

Fragment-Based Discovery and Structure-Led Optimization of MSC778, the First Potent, Selective, and Orally Bioavailable FEN1 Inhibitor.

Fragment-Based Discovery and Structure-Led Optimization of MSC778, the First Potent, Selective, and Orally Bioavailable FEN1 Inhibitor.

Journal: Journal of medicinal chemistry
Published: September 17, 2025

Design, development, and therapeutic applications of PARP-1 selective inhibitors.

Design, development, and therapeutic applications of PARP-1 selective inhibitors.

Journal: Future medicinal chemistry
Published: September 15, 2025

Niraparib Demonstrates Therapeutic Potential in Multiple Sclerosis through Inhibition of IL-17A Receptor Interaction and Promotion of Remyelination.

Niraparib Demonstrates Therapeutic Potential in Multiple Sclerosis through Inhibition of IL-17A Receptor Interaction and Promotion of Remyelination.

Journal: ACS chemical neuroscience
Published: September 09, 2025

Metabolic signatures of niraparib-resistant ovarian cancer cells based on non-target metabolomics

Metabolic signatures of niraparib-resistant ovarian cancer cells based on non-target metabolomics

Journal: Zhonghua fu chan ke za zhi
Published: August 25, 2025

Niraparib combined with anlotinib after PARPi resistance in ovarian cancer: A single-center retrospective study from China.

Niraparib combined with anlotinib after PARPi resistance in ovarian cancer: A single-center retrospective study from China.

Journal: European journal of obstetrics, gynecology, and reproductive biology
Published: August 16, 2025

Mechanistic insights into P-glycoprotein-driven transport of anti-cancer PARP inhibitors.

Mechanistic insights into P-glycoprotein-driven transport of anti-cancer PARP inhibitors.

Journal: Biochemical pharmacology
Published: July 14, 2025

Combinatorial organoid mutagenesis screen reveals gene constellations driving malignant transformation, pathology and chemosensitivity in high-grade serous ovarian carcinoma.

Combinatorial organoid mutagenesis screen reveals gene constellations driving malignant transformation, pathology and chemosensitivity in high-grade serous ovarian carcinoma.

Journal: bioRxiv : the preprint server for biology
Published: July 14, 2025

Correction: Severe thrombocytopenia induced by niraparib in ovarian cancer patients: a case report and literature review.

Correction: Severe thrombocytopenia induced by niraparib in ovarian cancer patients: a case report and literature review.

Journal: Frontiers in oncology
Published: July 08, 2025

Polymer-PARPi Conjugates Delivering USP1i for Maximizing Synthetic Lethality to Stimulate STING Pathway in High-Grade Serous Ovarian Cancer.

Polymer-PARPi Conjugates Delivering USP1i for Maximizing Synthetic Lethality to Stimulate STING Pathway in High-Grade Serous Ovarian Cancer.

Journal: Advanced materials (Deerfield Beach, Fla.)
Published: July 07, 2025

Effectiveness and Safety of PARP Inhibitors in Ovarian Cancer: An Umbrella Review of Systematic Reviews and Meta-Analyses.

Effectiveness and Safety of PARP Inhibitors in Ovarian Cancer: An Umbrella Review of Systematic Reviews and Meta-Analyses.

Journal: Critical reviews in oncology/hematology
Published: July 04, 2025

Emergence of PALB2 Reversion Mutations as a Mechanism of Resistance to Niraparib in Breast Cancer: A Case Report.

Emergence of PALB2 Reversion Mutations as a Mechanism of Resistance to Niraparib in Breast Cancer: A Case Report.

Journal: Cancer science
Published: July 04, 2025
Showing 1-12 of 827

Last Updated: 10/31/2025